Break out session on Neurodegeneration 2024

Welcome to this years Neurodegeneration session chaired by:
Dr. Daniel Ferreira, Karolinska Institutet
Dr. Amit Kumar, Karolinska Institutet
Dr. Baayla Boon, Mayo Clinic
Dr. Christopher Schwarz, Mayo Clinic

Venue 16 October: Kerstin Hagenfeldt ( J3:14) Bioclinicum, Karolinska Hospital,
Venue 17 October; Scheelesalen Tomtebodavägen 6,

Wednesday Oct 16
Thursday Oct 17

14:00pm (Sweden)

Involvement of intracellular adhesion molecule 1 (ICAM1) in the secondary insults associated with reactive astrogliosis in Parkinson’s disease

Dr. Avishek Roy, PhD, Karolinska Institutet

14:08 pm (Sweden)

Structural brain MRI markers associated with odor identification decline

Dr. Javier Oltra, PhD, Karolinska Institutet

14:36 pm (Sweden)

Repopulation with tolerogenic MHC-mismatched microglia-like cells as a therapeutic approach in MS

Dr. Irene Benito Cuesta, PhD, Karolinska Institutet

14:55 (Sweden)

Break

15:00 (Sweden)

Neuropathology after treatment with aducanumab and amyloid related imaging abnormalities

Dr. Baayla Boon, MD, PhD, Mayo Clinic

15:18 pm (Sweden)

Assessment of innate and adaptive immune response in a novel humanized mouse model of Alzheimer’s disease

Dr. Ruchi Gera, PhD, Karolinska Institutet

15:36 pm (Sweden)

Amyloid Beta influences plasmin activity in-vitro – relevance for Alzheimer's Disease

Dr. Aditya Kumar Kar, PhD, Karolinska Institutet

15:55 pm (Sweden)

Break

16:00 pm (Sweden)

Characterization of a limbic-predominant amnestic neurodegenerative syndrome

Dr. Nick Corriveau-Lecavalier, PhD, Mayo Clinic

16:18 pm (Sweden)

Alpha-synuclein RT-QuIC for Dementia with Lewy bodies

Dr. Rakesh Kumar, PhD, Karolinska Institutet

16:36 pm (Sweden)

Markers of cerebrovascular disease in Dementia with Lewy bodies

Ms. Anna Rennie, Karolinska Institutet

17:00 pm (Sweden)

End of session

2.30 pm (Sweden)

Transitions and critical points in young-onset dementia

Dr. Malin Aspö, Karolinska Institutet, Karolinska University Hospital

14:48 pm (Sweden)

Patients with dementia with Lewy bodies display alterations in their cognitive connectome from prodromal stages

Ms. Roraima Yanez-Perez, Karolinska Institutet, University of La Laguna

15:06 pm (Sweden)

Blood biomarkers of Alzheimer’s disease and transitions from normal cognition to cognitive impairment and dementia: a population-based study

Dr. Martina Valletta, MD, Karolinska Institutet

15:25 pm (Sweden)

Break

15:30 pm (Sweden)

A Comparative Analysis of Polygenic Risk Scores for Predicting ADRD in UK Biobank

Dr. Shayan Mostafaei, PhD, Karolinska Institutet

15:48 pm (Sweden)

Hippocampal cholinergic activity is altered in an APP-knock-in (AppNL-G-F) AD mice model

Dr. Sumonto Mitra, PhD, Karolinska Institutet

16:06 pm (Sweden)

A multiple-drug therapy benefits cognition and reduces amyloid plaques in APP NL-G-F knock-in mice, in a sex-specific manner.

Francesca Eroli, Karolinska Institutet

16:25 pm (Sweden)

Break

16;30 pm (Sweden)

Comparing de-facing software MiDeFace and mri_reface according to privacy protection and effects on downstream measurements

Dr. Christopher Schwarz, PhD, Mayo Clinic

16:48 pm (Sweden)

In Vivo and Post-Mortem Validation of Imaging-based Cholinergic Biomarkers in Alzheimer's and Dementia with Lewy Body

Dr. Milan Nemy, PhD, Karolinska Institutet

17:00 pm (Sweden)

Neuronal alterations during the onset of Alzheimer’s disease in the human brain cortex

Dr. Luis Enrique Arroyo Garcia, PhD, Karolinska Institutet